IPSEN (OTCMKTS:IPSEY) Hits New 52-Week High - Should You Buy?

Key Points

• Shares of IPSEN hit a new 52-week high, reaching $49.15 in mid-day trading (volume ~100 shares) and were up about 1.3% from the prior close.
• Analysts are mixed with a MarketBeat consensus of "Hold"; UBS recently downgraded IPSEN from strong-buy to hold while Deutsche Bank maintained a buy rating (ratings: 1 Buy, 1 Hold, 1 Sell).
• Ipsen is a global biopharmaceutical focused on oncology, neuroscience and rare diseases, with key oncology products including Cabometyx and Decapeptyl.

Shares of IPSEN (OTCMKTS:IPSEY - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $49.15 and last traded at $49.15, with a volume of 100 shares traded. The stock had previously closed at $48.54.

Wall Street Analysts Forecast Growth

IPSEY has been the subject of a number of analyst reports. UBS Group downgraded IPSEN from a "strong-buy" rating to a "hold" rating in a research note on Thursday, January 8th. Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of IPSEN in a report on Tuesday. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, IPSEN currently has a consensus rating of "Hold".

IPSEN Stock Up 1.3%

The business has a fifty day moving average of $45.18 and a two-hundred day moving average of $39.22.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company's oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.